Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
NCT07468383

Basic and Clinical Study of Cardiac Ganglion Catheter Ablation for the Treatment of Significant Bradycardia

Led by Beijing Anzhen Hospital · Updated on 2026-03-13

188

Participants Needed

1

Research Sites

156 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study adopts a strategy combining basic research with clinical investigation to systematically explore the therapeutic value of cardioneuroablation in the treatment of vagally-mediated bradycardia. The study design fully considers the complexity of the scientific question and the feasibility of clinical translation. Through rigorous experimental design and standardized operational procedures, the reliability and reproducibility of the study results are ensured.

CONDITIONS

Official Title

Basic and Clinical Study of Cardiac Ganglion Catheter Ablation for the Treatment of Significant Bradycardia

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age range: 18 - 65 years old
  • Experiencing symptoms related to bradycardia such as syncope, dizziness, blackout, palpitations, fatigue, listlessness, inability to concentrate, or reduced activity endurance
  • Have either an average heart rate below 50 beats per minute or a heart arrest lasting more than 3 seconds during the day as shown by dynamic electrocardiogram
  • Have transient second or third degree atrioventricular conduction block without hemodynamic disorders during the day
  • Atropine test results showing sinus heart rate increase by at least 25%, or heart rate of 90 beats per minute or higher, or improvement of atrioventricular conduction block to no more than first-degree block
Not Eligible

You will not qualify if you...

  • History of severe trauma caused by bradycardia
  • Regular use of antiarrhythmic drugs within the past 3 months
  • Previous cardiac pacemaker implantation
  • Existing or indicated implantation of electronic devices with pacing function such as CCMs, ICDs, or CRT devices
  • Bradycardia or atrioventricular block caused by medications or reversible conditions like hyperkalemia or hypothyroidism
  • Bradycardia or atrioventricular block linked to obstructive sleep apnea syndrome
  • Coronary revascularization within the past 3 months or unstable coronary heart disease despite treatment
  • Stroke or transient ischemic attack within the past 3 months
  • History of open-heart surgery
  • Severe congenital heart disease
  • Severe ventricular arrhythmia
  • Severe cardiac insufficiency with left ventricular ejection fraction 35% or less
  • Severe cardiomyopathy including hypertrophic obstructive, dilated, or cardiac amyloidosis
  • Severe aortic or mitral valve stenosis
  • Pregnancy or breastfeeding
  • Expected survival less than 1 year
  • Refusal to sign informed consent
  • Other conditions deemed ineligible by researchers

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Beijing Anzhen Hospital, Capital Medical University

Beijing, China, China, 100029

Actively Recruiting

Loading map...

Research Team

L

Liu He, PhD.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here